Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results

Rhea-AI Summary

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported its third quarter 2020 financial results, showing revenues of approximately $1.1 million, up from $0.9 million in Q3 2019. The company announced a strategic restructuring, focusing on ProNeura® development and discontinuing U.S. Probuphine implant sales. It raised approximately $8.1 million from direct and public offerings and settled all debt obligations. Despite increased operating expenses of $5.8 million, Titan aims to implement its new strategy post-restructuring. The net loss for the quarter was $4.9 million, or $0.05 per share.

Positive

• Raised approximately $8.1 million from direct and public offerings.
• Completed restructuring to focus on ProNeura® development, potentially enhancing growth.
• Settled all debt obligations, improving financial flexibility.

Negative

• Net loss increased to approximately $4.9 million, up from $2.8 million in Q3 2019.
• Product sales declined due to reduced unit sales, patient assistance program utilization, and COVID-19 impacts.
• Operating expenses rose to approximately $5.8 million from $4.8 million in Q3 2019.

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended September 30, 2020 and provided an update on its business.

Third Quarter 2020 and Recent Highlights

• In September 2020, the Company completed a registered direct offering, resulting in net cash proceeds of approximately $2.4 million.
• In October 2020, Titan announced a strategic restructuring, where it will focus on ProNeura^®-based product development; and discontinue its U.S. Probuphine implant sales and wind down Probuphine commercialization activities.
• In October 2020, Kate DeVarney, Ph.D., was promoted from the position of Executive Vice President and Chief Scientific Officer to President and Chief Operating Officer. In addition, Sunil Bhonsle stepped down from his executive role. Dr. Marc Rubin, Titan's Executive Chairman, together with Dr. DeVarney, will oversee the Company's product development activities.
• In October 2020, Titan completed a public offering resulting in net cash proceeds of approximately $5.7 million.
• In October 2020, the Company settled all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A and Horizon Credit LLC II.
• In October 2020, Titan acquired JT Pharmaceuticals, Inc.'s kappa opioid agonist peptide, JT-09, for use in combination with Titan's ProNeura^® long-term, continuous drug delivery technology, for the treatment of chronic pruritus.

"Subsequent to the end of the third quarter, Titan began an important, focused restructuring to position the Company for future growth," said Dr. DeVarney. "We believe that our ProNeura platform, which has the potential to provide continuous drug delivery over extended periods of up to six to 12 months, offers potential key value-generating opportunities. These include the platform's application to the recently-acquired JT-09, for which we plan to establish proof-of-concept as a treatment of chronic pruritus in the first half of next year. In addition, we remain committed to helping individuals impacted by the opioid epidemic through our ongoing, National Institute on Drug Abuse-funded nalmefene implant development program, with plans to file an investigational New Drug Application with the U.S. Food and Drug Administration in the first half of 2021."

"In addition to refocusing our efforts on the ProNeura platform, our recent restructuring significantly reduced operating expenses, while our debt settlements restored our ability to fully capitalize on our IP," said Dr. Rubin. "These, combined with the recent completion of two financings, positions Titan to execute on our new strategy."

Third Quarter 2020 Financial Results 

For the three months ended September 30, 2020, Titan reported approximately $1.1 million in revenue, which reflects approximately $0.1 million in product sales and approximately $1.0 million related to the Company's National Institute on Drug Abuse ("NIDA") grant. This compared with revenues of approximately $0.9 million in the same period in 2019, which was comprised of $0.2 million in product sales and $0.8 million related to the NIDA grant. Product revenue during the three month period ended September 30, 2020 declined from the comparable periods in 2019 due to a substantial decrease in unit sales volumes; increased utilization of patient assistance programs; and the effects of the COVID-19 pandemic and the related shelter-in-place restrictions and clinic closures. 

Total operating expenses for the third quarter of 2020 were approximately $5.8 million, compared with approximately $4.8 million from the same quarter in 2019, and consisted primarily of research and development ("R&D") and selling, general and administrative ("SG&A") expenses and costs of goods sold, inclusive of distribution expenses. R&D expenses for the quarter ended September 30, 2020 were approximately $1.6 million, consistent with the same three month period in 2019. SG&A expenses for the 2020 third quarter were approximately $3.5 million, compared with approximately $3.0 million in the same quarter a year ago. Costs of goods sold for the third quarter of 2020 were approximately $0.7 million, compared with approximately $0.2 million the 2019 third quarter.

Net other expense, consisting primarily of interest expense, was approximately $0.3 million in the third quarter of 2020, compared with net other income of approximately $1.1 million in the third quarter of 2019. The increase in other expense, net for the three months ended September 30, 2020 was primarily due to an approximately $1.0 million non-cash gain on changes in the fair value of warrants issued in connection with Titan's August 2019 offering and an approximately $0.3 million non-cash gain on debt extinguishment related to the modification of Titan's loan from Molteni.

Net loss applicable to common stockholders in the third quarter of 2020 was approximately $4.9 million, or approximately $0.05 per share, compared with a net loss applicable to common stockholders of approximately $2.8 million, or approximately $0.18 per share, in the same quarter in 2019.

As of September 30, 2020, Titan had cash and cash equivalents of approximately $4.1 million, which the Company believes, along with the proceeds of public offering, is sufficient to fund planned operations into the third quarter of 2021.

Conference Call Details

Titan management will host a conference call today at 12:00 p.m. ET / 9:00 a.m. PT to discuss business developments in the period. The conference call will be hosted by Marc Rubin, M.D., Executive Chairman, and Kate DeVarney, Ph.D., President and Chief Operating Officer.

The live conference call may be accessed by dialing 1-888-317-6003 (U.S.) or 1-412-317-6061 (international) and providing passcode 9502574. The call will also be broadcast live at https://www.webcaster4.com/Webcast/Page/1655/38848, and archived on Titan's website at www.titanpharm.com/news/events.    

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura^® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the winding down of U.S. commercial activities related to Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT:

Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com

 

TITAN PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share amount)
(unaudited)
					Three Months Ended September 30,				Nine Months Ended September 30,
					2020		2019		2020		2019
Revenue:
	License revenue				$            -		$             -		$              6		$          313
	Product revenue				102		190		427		811
	Grant revenue				1,018		757		3,348		1,270
		Total revenue			1,120		947		3,781		2,394
Operating expense:
	Cost of goods sold				683		188		1,081		738
	Research and development				1,562		1,619		5,846		5,370
	Selling, general and administrative				3,549		3,023		10,137		9,336
		Total operating expense			5,794		4,830		17,064		15,444
Loss from operations					(4,674)		(3,883)		(13,283)		(13,050)
		Other income (expense), net			(258)		1,080		(1,874)		533
Net loss and comprehensive loss					$     (4,932)		$      (2,803)		$   (15,157)		$   (12,517)
Basic and diluted net loss per common share					$       (0.05)		$        (0.18)		$       (0.17)		$       (0.89)
Weighted average shares used in computing
	basic and diluted net loss per share				97,906		15,517		91,848		14,112

CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)
							September 30,				December 31,
							2020				2019
Assets
	Cash and cash equivalents						$       4,073				$       5,223
	Receivables						423				993
	Inventory						1,073				998
	Prepaid expenses and other current assets						1,080				1,094
		Total current assets					6,649				8,308
	Property and equipment, net						1,161				817
	Operating lease right-of-use asset						208				397
		Total assets					$       8,018				$       9,522
Liabilities and Stockholders' Equity (Deficit)
	Current liabilities						$       5,877				$       3,600
	Operating lease liability, non-current						-				150
	Long-term debt, non-current						3,038				4,019
	Warrant liability						-				320
	Stockholders' equity (deficit)						(897)				1,433
		Total liabilities and stockholders' equity (deficit)					$       8,018				$       9,522

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-reports-third-quarter-2020-financial-results-301173387.html

SOURCE Titan Pharmaceuticals, Inc.

FAQ

What were Titan Pharmaceuticals' revenues in Q3 2020?

Titan Pharmaceuticals reported revenues of approximately $1.1 million for the third quarter of 2020.

What was the net loss for Titan Pharmaceuticals in Q3 2020?

The net loss applicable to common stockholders in Q3 2020 was approximately $4.9 million, or $0.05 per share.

What strategic changes did Titan Pharmaceuticals announce?

Titan announced a strategic restructuring to focus on ProNeura® product development and discontinue U.S. Probuphine implant sales.

How much cash did Titan Pharmaceuticals have as of September 30, 2020?

As of September 30, 2020, Titan had cash and cash equivalents of approximately $4.1 million.

What impact did COVID-19 have on Titan Pharmaceuticals' sales?

COVID-19 caused a decrease in unit sales volumes, impacting product revenue in Q3 2020.